1 min read
As the financial year-end approaches in Australia, sponsors must reassess their portfolios listed on the Australian Register of Therapeutic Goods (ARTG).
With annual charges applied to active entries, retaining inactive or obsolete products can lead to unnecessary regulatory costs and portfolio inefficiencies. This makes ARTG cancellation a critical activity during April–June for pharmaceutical and medical device sponsors.
Under the Therapeutic Goods Administration (TGA) framework, ARTG entries must be formally cancelled to avoid annual charges for the upcoming financial year.
Key considerations:
- Cancellation requests must be submitted before 5:00 pm, 30 June
• Only sponsors (not agents) can initiate cancellation via TGA Business Services (TBS)
• Online submissions are processed faster than paper-based requests
• Missed deadlines result in automatic ARTG annual charges
Understanding the ARTG cancellation process is essential to ensure timely execution and cost control.
Despite clear guidelines, sponsors often encounter:
- Missed cancellation deadlines due to internal coordination delays
• Limited visibility across ARTG-listed product portfolios
• Retention of inactive or low-commercial-value entries
• Errors or delays in submission via TGA Business Services
• Lack of structured lifecycle management (LCM) processes
These challenges can lead to avoidable fees, compliance risks, and operational inefficiencies.
Freyr supports sponsors with practical, execution-focused ARTG lifecycle support aligned with TGA requirements:
ARTG Portfolio Review to identify entries that may no longer be required
Submission Support via TBS to ensure accurate and timely cancellation requests
Documentation Checks to minimize errors or delays
Deadline-Oriented Planning to support submissions ahead of 30 June
Ongoing Lifecycle Management (LCM) including regulatory query handling and post-approval updates
Outcome: Optimized portfolios, reduced unnecessary ARTG annual charges, and improved compliance oversight.
For global companies, managing ARTG entries alongside other markets can be complex.
Freyr helps align global product portfolios with Australia-specific regulatory requirements, ensuring that local obligations, such as ARTG maintenance and cancellations are not overlooked.
In Australia, regulatory strategy is not only about gaining approval it’s also about maintaining an efficient and compliant portfolio.
Are you carrying ARTG entries that no longer add value, but still incur costs?
With the 30 June ARTG cancellation deadline approaching, early action can help avoid unnecessary charges.
Request a targeted ARTG portfolio review with Freyr to identify entries suitable for cancellationConnect with our team for practical support on ARTG lifecycle management and submissions
